New York State Common Retirement Fund Trims Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

New York State Common Retirement Fund lowered its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 30.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,224 shares of the company's stock after selling 57,375 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Cellebrite DI worth $2,569,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Catalyst Capital Advisors LLC bought a new position in shares of Cellebrite DI in the 1st quarter worth $51,000. Gen Wealth Partners Inc acquired a new position in shares of Cellebrite DI in the fourth quarter valued at about $85,000. NewEdge Advisors LLC increased its holdings in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Cellebrite DI in the first quarter valued at about $269,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter worth about $274,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on CLBT shares. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a research note on Friday, June 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $22.43.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT traded down $0.26 during trading on Friday, reaching $14.32. The stock had a trading volume of 1,071,768 shares, compared to its average volume of 1,550,164. Cellebrite DI Ltd. has a fifty-two week low of $11.90 and a fifty-two week high of $26.30. The business's 50-day moving average price is $15.80 and its 200-day moving average price is $18.70. The company has a market cap of $3.43 billion, a P/E ratio of -14.92, a PEG ratio of 2.89 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. The firm had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. Cellebrite DI's revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 EPS. Analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.